Invivo Rat anti-Mouse CD276 Recombinant mAb

產(chǎn)品型號(hào)：S0B1361

更新時(shí)間：2025-07-15

廠商性質(zhì)：生產(chǎn)廠家

訪問量：78

服務(wù)熱線

15855403091

立即咨詢

產(chǎn)品分類

PRODUCT CLASSIFICATION

抗體/抗原

ELISA試劑盒抗體試劑盒二抗試劑盒二抗其它流式抗體瓊脂糖/磁珠偶聯(lián)抗體抗Payload抗體泛修飾抗體標(biāo)簽/內(nèi)參抗體功能性抗體 Biosimilar抗體偶聯(lián)抗體配對抗體病理/IHC抗體

查看全部產(chǎn)品

相關(guān)文章

斯達(dá)特特色產(chǎn)品推薦之：PD-1 功能性抗體

視黃醇結(jié)合蛋白4（RBP4）抗體：發(fā)掘其在疾病風(fēng)險(xiǎn)中的診斷潛力

IHC腫瘤標(biāo)志物 | 常見乳腺癌診斷——助力守護(hù)生命之花

基因治療中重要的AAV抗體

產(chǎn)品介紹

CD276 （B7-H3） is an immune checkpoint molecule belonging to the B7 family and encodes a type I transmembrane protein. It plays a role in regulating T cell-mediated immune responses. CD276 is highly expressed in various tumor cells and tumor-infiltrating immune cells, aiding tumor cells in evading immune surveillance and promoting tumor proliferation, metastasis, and treatment resistance. Additionally, CD276 is associated with cancer stem cell properties, and its high expression is linked to poor prognosis. Currently, several targeted therapies against CD276, including monoclonal antibodies, bispecific antibodies, antibody-drug conjugates （ADCs）, and CAR-T cell therapies, are under development and in clinical trials, showing promising anti-tumor potential.

上一個(gè)：S0B4059Goat Anti-Mouse IgG (H+L) (min X Hu, Bov Sr Prot)